Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has officially opened its new facilities at Charnwood Campus, Loughborough.
Charnwood Molecular has become the sole occupier of a three-storey laboratory facility at Charnwood Campus which will house over 150 scientists. With the company’s recent acquisition of Aurelia Bioscience, they are now well prepared for the next exciting phase of their development as a company focused on discovery and innovation. The company is able to provide a fully integrated drug discovery solution to its clients, with teams across all disciplines working in the space.
Bringing their new market leading laboratories online has quadrupled their capacity.
Not only has this enabled them to better serve their existing global client base, many of whom have come on board during a period of strong growth for Charnwood Molecular in recent years, but it will also support further expansion across a range of the company’s services.
This includes a host of pre-clinical discovery core activities including assay development, computational and medicinal chemistry, early process research and chemical development as well as a whole suite of others which sit alongside to complement these.
The site was officially opened at a formal ceremony on the 7th April by Lord-Lieutenant of Leicestershire, Mr Michael Kapur OBE, who is the Queen’s representative in the county.
Charnwood Molecular is ideally placed now to offer an ever-expanding number of services.
The company’s project-proven capabilities include bioscience, computational chemistry, medicinal chemistry and process research & development. It’s clear that the company can work with clients right through the drug discovery process, from target identification through to lead identification, compound optimisation and onwards to scale-up. Time is saved and value added by cutting out inefficiencies along the way, ensuring that clients’ compounds are in the best possible position for future market success.
Founder and CEO of Charnwood Molecular, Steve Allin, commented: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories provide substantial capacity for future growth and expansion of our current scientific teams, along with the future addition of related drug discovery service lines.”
ABOUT CHARNWOOD MOLECULAR
In 2019 Charnwood Molecular was acquired by leading Private Equity group, Synova. The deal provided the company with additional investment to support its continued development and growth. Synova continues to support Charnwood Molecular to deliver an ambitious growth plan, built upon increasing investment in the business’s core capabilities as a trusted partner in innovative chemistry, alongside expanding its service offering into complementary scientific disciplines.
In 2022 Charnwood Molecular relocated its BioCity and Loughborough operations to a single-site, state-of-the-art laboratory complex based in world-class facilities at Charnwood Campus, Loughborough. The campus was recently designated a “Life Sciences Opportunity Zone”, providing an environment to inspire discovery, encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.
Charnwood Molecular’s portfolio of services is wide and currently includes:
- Fully integrated drug discovery
- Customised bioassay development
- Medicinal Chemistry (design, synthesis and multi-parameter optimisation of drug molecules for discovery projects; computational chemistry and emerging synthetic technologies)
- Custom Synthesis preparation of key chemical intermediates on up to 20-litre scale
- Chemical Development and Process Research Services including route design, development and optimization
Editorial enquiries to Paul Hughes, Smarter Marketing.
T: 07931 903 628